Long-Term Innohep速 Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
The purpose of this study is to assess the efficacy and safety of Innohep速 in preventing the recurrence of VTE in patients with active cancer who have had an acute VTE episode.
Venous Thromboembolism
DRUG: Warfarin|DRUG: Innohep速
Composite end-point represented by the time in days from randomisation to the first occurrence of VTE, * Symptomatic non-fatal DVTs.
* Symptomatic non-fatal PEs.
* Fatal PE.
* Incidental proximal DVT (popliteal vein or higher).
* Incidental proximal PE (segmental arteries or larger)., 6 months
Time in days from randomisation to the first occurrence of VTE., * The 5 individual components of the composite primary efficacy endpoint.
* A composite endpoint of symptomatic DVT and/or PE, including fatal PE.

Safety endpoints will consist of bleeding and overall mortality, 6 months
The purpose of this study is to assess the efficacy and safety of Innohep速 in preventing the recurrence of VTE in patients with active cancer who have had an acute VTE episode.